

Uwe Pelzer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2018528/uwe-pelzer-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83
papers

2,930
citations

24
h-index

53
g-index

94
ext. papers

3,547
ext. citations

4.8
avg, IF

4.44
L-index

#	Paper	IF	Citations
83	Treatment of Intrahepatic Cholangiocarcinoma-A Multidisciplinary Approach.. <i>Cancers</i> , 2022 , 14,	6.6	4
82	Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCII expression.. <i>Nature Communications</i> , 2022 , 13, 156	17.4	4
81	Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials. <i>European Journal of Cancer</i> , 2021 , 150, 250-259	7.5	1
80	A tailored approach in lymph node-positive perihilar cholangiocarcinoma. <i>Langenbeck's Archives of Surgery</i> , 2021 , 406, 1499-1509	3.4	3
79	Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 128-138	18.8	26
78	Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. <i>Frontiers in Oncology</i> , 2021 , 11, 670396	5.3	4
77	PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer 2021 , 9,		6
76	Safety, Efficacy and Pharmacokinetics of Targeted Therapy with The Liposomal RNA Interference Therapeutic Atu027 Combined with Gemcitabine in Patients with Pancreatic Adenocarcinoma. A Randomized Phase Ib/IIa Study. <i>Cancers</i> , 2020 , 12,	6.6	12
75	Ultrasound Time-Harmonic Elastography of the Pancreas: Reference Values and Clinical Feasibility. <i>Investigative Radiology</i> , 2020 , 55, 270-276	10.1	5
74	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1940-1951	15.4	24
73	Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). <i>Annals of Oncology</i> , 2020 , 31, 79-87	10.3	18
72	Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG). <i>BMJ Open</i> , 2020 , 10, e035546	3	3
71	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020 , 7, e746-e755	14.6	8
70	Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 3732-3739	12.9	13
69	Split-bolus vs. multiphasic contrast bolus protocol in patients with pancreatic cancer or cholangiocarcinoma. <i>European Journal of Radiology</i> , 2019 , 119, 108626	4.7	3
68	Ist nicht obligat: histologische Sicherung vor neoadjuvanter Therapie des Pankreaskarzinoms. <i>Onkologe</i> , 2019 , 25, 658-660	0.1	
67	Influence of the body mass index on postoperative outcome and long-term survival after pancreatic resections in patients with underlying malignancy. <i>Hepatobiliary Surgery and Nutrition</i> , 2019 , 8, 201-210	2.1	2

66	Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis. <i>Anticancer Research</i> , 2019 , 39, 5781-5787	2.3	1
65	APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4000-4000	2.2	78
64	A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 330-330	2.2	1
63	Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS725-TPS725	2.2	
62	Strengths, Weaknesses, Opportunities, and Threats of Centralized Pancreatic Surgery: a Single-Center Analysis of 3000 Consecutive Pancreatic Resections. <i>Journal of Gastrointestinal Surgery</i> , 2019 , 23, 492-502	3.3	1
61	Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. <i>Leukemia</i> , 2018 , 32, 1908-1919	10.7	75
60	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology, The</i> , 2018 , 19, e151-e160	21.7	31
59	Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis. <i>European Journal of Cancer</i> , 2018 , 100, 85-93	7.5	3
58	Sequence therapy in metastatic pancreatic cancer. <i>Zeitschrift Fur Gastroenterologie</i> , 2018 , 56, 578-582	1.6	1
57	Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy: Interim results of a randomized phase II AIO trial (NEOLAP).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 348-348	2.2	8
56	A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS524-TPS524	2.2	
55	Pankreaskarzinom □Therapiestandards und spezielle Situationen. <i>Best Practice Onkologie</i> , 2018 , 13, 238-246		
54	The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. <i>Surgical Oncology</i> , 2018 , 27, 688-694	2.5	14
53	The Falciform Ligament for Mesenteric and Portal Vein Reconstruction in Local Advanced Pancreatic Tumor: A Surgical Guide and Single-Center Experience. <i>HPB Surgery</i> , 2018 , 2018, 2943879		11
52	Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. <i>British Journal of Cancer</i> , 2018 , 118, 1485-1491	8.7	23
51	Routine portal vein resection for pancreatic adenocarcinoma shows no benefit in overall survival. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1094-1099	3.6	8
50	Quality-adjusted survival with combination nab-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. <i>British Journal of Cancer</i> , 2017 , 116, 1247-1253	8.7	21
49	Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients. <i>PLoS ONE</i> , 2017 , 12, e0186341	3.7	12

48	CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3330-3337	2.2	143
47	Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2017 , 83, 290-301	7.5	49
46	Influence of cytotoxic tumor-infiltrating T lymphocytes on outcome in resectable pancreatic cancer: Results from the CONKO 001 trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 281-281	2.2	1
45	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 545-557	4.0	630
44	A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 385-385	2.2	24
43	Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 248-57	3.4	18
42	Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review. <i>World Journal of Gastrointestinal Oncology</i> , 2016 , 8, 258-70	3.4	13
41	Nabpaclitaxel plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubinemia secondary to bile duct obstruction.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15717-e15717	2.2	2
40	Quality-adjusted time without symptoms or toxicity (Q-TWiST) of nanoliposomal irinotecan (nal-IRI; MM-398) plus 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma (mPAC) patients (pts) previously treated with gemcitabine-based therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15732-e15732	2.2	
39	Reply to M.G. McNamara et al and T.H. Oo. <i>Journal of Clinical Oncology</i> , 2016 , 34, 516-7	2.2	5
38	Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group. <i>Pancreas</i> , 2016 , 45, 601-5	2.6	17
37	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. <i>BMJ Open</i> , 2016 , 6, e010569	3	14
36	P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. <i>Pathology Research and Practice</i> , 2016 , 212, 726-34	3.4	15
35	Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. <i>European Journal of Cancer</i> , 2015 , 51, 1546-54	7.5	35
34	Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy. <i>Pancreas</i> , 2015 , 44, 930-6	2.6	16
33	Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2015 , 112, 66-71	2.8	2
32	Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2028-34	2.2	172
31	CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks: A prospective randomized phase III study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4007-4007	2.2	17

30	Is gemcitabine (G) reuse possible in early recurrences after its adjuvant application in pancreatic adenocarcinoma (PA) treatment?. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15219-e15219	2.2	
29	Outcomes of gemcitabine (Gem)-based palliative first-line therapy in the treatment of recurrent disease or of initially unresectable pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15218 ^{2,2} -e15218		
28	SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. <i>Annals of Oncology</i> , 2014 , 25, 1025-32	10.3	63
27	Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2423-9	2.2	313
26	Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial. <i>BMC Cancer</i> , 2014 , 14, 204	4.8	12
25	Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. <i>British Journal of Cancer</i> , 2014 , 111, 1917-23	8.7	89
24	Prognostic factors for long-term survival in patients with ampullary carcinoma: the results of a 15-year observation period after pancreaticoduodenectomy. <i>HPB Surgery</i> , 2014 , 2014, 970234		42
23	Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4124-4124 ^{2,2}	2.2	6
22	First-line nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer from routine clinical practice. <i>In Vivo</i> , 2014 , 28, 1135-40	2.3	6
21	Cancer-related neuropathic pain in out-patient oncology clinics: a European survey. <i>BMC Palliative Care</i> , 2013 , 12, 41	3	24
20	Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. <i>Journal of Surgical Oncology</i> , 2013 , 108, 398-402	2.8	29
19	Blood group determinates incidence for pancreatic cancer in Germany. <i>Frontiers in Physiology</i> , 2013 , 4, 118	4.6	21
18	Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. <i>Frontiers in Oncology</i> , 2013 , 3, 155	5.3	21
17	Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. <i>Archives of Medical Science</i> , 2013 , 9, 261-7	2.9	8
16	The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. <i>Gastroenterology Research and Practice</i> , 2012 , 2012, 939350	2	43
15	Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany. <i>Onkologie</i> , 2012 , 35, 755-60		0
14	CONKO-008: Oxaliplatin (O)/folinic acid (FA)/5-fluorouracil (5-FU) (24h) in combination with lapatinib as second-line therapy in pancreatic cancer after gemcitabine failure: A phase I trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14533-e14533	2.2	
13	Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. <i>European Journal of Cancer</i> , 2011 , 47, 1676-81	7.5	261

12	First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1173-8	3.5	6
11	Fechtner syndrome--a myosin heavy chain 9 disorder--and pregnancy. <i>International Journal of Gynecology and Obstetrics</i> , 2010 , 109, 163-4	4	3
10	Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. <i>BMC Cancer</i> , 2010 , 10, 86	4.8	48
9	Second-line therapy in refractory pancreatic cancer. results of a phase II study. <i>Oncology Research and Treatment</i> , 2009 , 32, 99-102	2.8	18
8	Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009 , 3, S43-7		2
7	Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). <i>BMC Cancer</i> , 2008 , 8, 361	4.8	61
6	First-line chemotherapy in advanced pancreatic cancer. <i>Recent Results in Cancer Research</i> , 2008 , 177, 57-60	1.5	6
5	Second-line chemotherapy in advanced pancreatic cancer. <i>Recent Results in Cancer Research</i> , 2008 , 177, 61-4	1.5	3
4	Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. <i>Pancreatology</i> , 2005 , 5, 266-72	3.8	116
3	Role of F18-FDG PET for monitoring of radiochemotherapy -- estimation of detectable number of tumour cells. <i>Oncology Research and Treatment</i> , 2004 , 27, 287-90	2.8	4
2	A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. <i>Annals of Oncology</i> , 2000 , 11, 1267-72	10.3	39
1	Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. <i>Anti-Cancer Drugs</i> , 1999 , 10, 699-704	2.4	20